Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Payables (2021 - 2025)

Kiniksa Pharmaceuticals International's Payables history spans 5 years, with the latest figure at $2.0 million for Q4 2025.

  • For Q4 2025, Payables fell 0.54% year-over-year to $2.0 million; the TTM value through Dec 2025 reached $2.0 million, down 0.54%, while the annual FY2025 figure was $2.0 million, 0.54% down from the prior year.
  • Payables reached $2.0 million in Q4 2025 per KNSA's latest filing, down from $6.1 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $9.0 million in Q2 2025 to a low of $648000.0 in Q2 2023.
  • Average Payables over 5 years is $4.0 million, with a median of $2.6 million recorded in 2021.
  • The largest YoY upside for Payables was 1040.9% in 2024 against a maximum downside of 75.27% in 2024.
  • A 5-year view of Payables shows it stood at $1.9 million in 2021, then surged by 322.86% to $7.9 million in 2022, then grew by 4.39% to $8.2 million in 2023, then crashed by 75.27% to $2.0 million in 2024, then dropped by 0.54% to $2.0 million in 2025.
  • Per Business Quant, the three most recent readings for KNSA's Payables are $2.0 million (Q4 2025), $6.1 million (Q3 2025), and $9.0 million (Q2 2025).